Gabrielle Campbell
Overview
Explore the profile of Gabrielle Campbell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1476
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Hopkins R, Campbell G, Degenhardt L, Nielsen S, Blyth F, Cohen M, et al.
Pain
. 2021 Sep;
163(6):1049-1059.
PMID: 34538842
Although multimodal management of chronic noncancer pain (CNCP) is recommended, long-term treatment utilization patterns among people using opioids are not well known. The Pain and Opioids IN Treatment study recruited...
22.
Campbell G, Darke S, Hall W, Lappin J
Addiction
. 2021 Aug;
116(12):3273-3275.
PMID: 34382271
No abstract available.
23.
Santo Jr T, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al.
JAMA Psychiatry
. 2021 Jun;
78(9):979-993.
PMID: 34076676
Importance: Mortality among people with opioid dependence is higher than that of the general population. Opioid agonist treatment (OAT) is an effective treatment for opioid dependence; however, there has not...
24.
Degenhardt L, Hungerford P, Nielsen S, Bruno R, Larance B, Clare P, et al.
JAMA Netw Open
. 2021 Apr;
4(4):e213059.
PMID: 33835176
Importance: Despite concern about harms related to long-term prescribed opioid use among individuals with chronic noncancer pain (CNCP), no study has examined whether the same patients engage in a risky...
25.
Santo Jr T, Campbell G, Gisev N, Tran L, Colledge S, Di Tanna G, et al.
Drug Alcohol Depend
. 2021 Jan;
219:108459.
PMID: 33401031
Background: Experience of childhood maltreatment (CM) is a risk factor for opioid use disorder (OUD). CM is also associated with comorbid mental disorders and poor treatment outcomes among people with...
26.
Nielsen S, Gisev N, Leung J, Clare P, Bruno R, Lintzeris N, et al.
Br J Clin Pharmacol
. 2020 Dec;
87(8):3092-3104.
PMID: 33368473
Aims: Pregabalin has become widely used as an alternative to opioids in treating certain types of chronic non-cancer pain, but few studies have examined its clinical efficacy outside trials. We...
27.
Campbell G, Noghrehchi F, Nielsen S, Clare P, Bruno R, Lintzeris N, et al.
EClinicalMedicine
. 2020 Dec;
28:100592.
PMID: 33294810
Background: The literature suggests patient characteristics and higher opioid doses and long-term duration are associated with problematic opioid behaviours but no one study has examined the role of all these...
28.
Sutherland R, Dietze P, Gisev N, Bruno R, Campbell G, Memedovic S, et al.
Drug Alcohol Rev
. 2020 Jun;
39(5):568-574.
PMID: 32557912
Introduction And Aims: Pregabalin is a gamma-aminobutyric acid analogue registered and subsidised for the treatment of neuropathic pain in Australia. Despite pre-clinical evidence of low abuse potential, there are increasing...
29.
Zahra E, Darke S, Degenhardt L, Campbell G
Drug Alcohol Depend
. 2020 May;
212:108028.
PMID: 32370933
Background: The most commonly used illicit substance worldwide is cannabis. To date, no national level study of cannabis-related death has been undertaken in Australia. The current study aimed to investigate...
30.
Campbell G, Darke S, Degenhardt L, Townsend H, Carter G, Draper B, et al.
Suicide Life Threat Behav
. 2020 Mar;
50(4):778-791.
PMID: 32162732
Objective: The aims were to estimate the prevalence of CNCP in suicide decedents, and compare sociodemographic and clinical characteristics of people who die by suicide (i) with and without a...